Pathogenesis of prostate cancer and hormone refractory prostate cancer.
Prostate cancer is the second most common malignancy in males and the leading cause of cancer death. Prostate cancer is initially androgen dependent and relies upon the androgen receptor (AR) to mediate the effects of androgens. The AR is also the target for therapy using antiandrogens and LHRH analogues. However, all cancers eventually become androgen independent, often referred to as hormone refractory prostate cancer. The processes involved in this transformation are yet to be fully understood but research in this area has discovered numerous potential mechanisms including AR amplification, over-expression or mutation and alterations in the AR signaling pathway. This review of the recent literature examines the current knowledge and developments in the understanding of the molecular biology of prostate cancer and hormone refractory prostate cancer, summarizing the well characterized pathways involved as well as introducing new concepts that may offer future solutions to this difficult problem.
Girling
J S
JS
CRUK Uro-oncolgy Group, Department of Oncology, University of Cambridge, Hutchison/MRC Research Centre, Cambridge, CB2 2XZ, UK.
Whitaker
H C
HC
Mills
I G
IG
Neal
D E
DE
Cancer. 1993 Dec 15;72(12 Suppl):3888-95
8252511
J Pathol. 2005 Mar;205(4):522-9
15685688
Br J Cancer. 2006 Jun 19;94(12):1906-12
16721361
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7379-84
9636157
Br J Cancer. 2004 Jan 26;90(2):449-54
14735192
Prostate. 2004 Nov 1;61(3):276-90
15368471
Endocr Rev. 1999 Jun;20(3):321-44
10368774
Clin Cancer Res. 2004 Feb 1;10(3):1032-40
14871982
Cancer Res. 2001 May 1;61(9):3550-5
11325816
Mol Endocrinol. 1999 Jan;13(1):117-28
9892017
FEBS Lett. 2002 Jul 17;523(1-3):43-7
12123801
Traffic. 2005 Dec;6(12):1103-13
16262722
Cancer Res. 2004 Jan 15;64(2):765-71
14744796
Urology. 1995 Mar;45(3):542-9
7879350
Lab Invest. 2001 Dec;81(12):1647-51
11742035
Cell. 1997 Aug 8;90(3):569-80
9267036
Nat Med. 2000 Jun;6(6):703-6
10835690
Anticancer Res. 2005 Nov-Dec;25(6C):4595-8
16334148
Prostate Suppl. 1989;2:33-50
2482772
Cancer Res. 1997 Jan 15;57(2):314-9
9000575
Cancer Res. 2005 Sep 1;65(17):7959-67
16140968
Biochem J. 2004 Oct 15;383(Pt 2):267-76
15239671
Clin Cancer Res. 2004 Nov 1;10(21):7121-6
15534082
J Mol Endocrinol. 2000 Jun;24(3):339-51
10828827
J Urol. 2001 Oct;166(4):1514-9
11547123
Int J Cancer. 2006 Mar 1;118(5):1108-19
16161052
Cancer. 2006 Jun 15;106(12):2743-52
16703599
Nat Genet. 1995 Apr;9(4):401-6
7795646
Urology. 2001 Aug;58(2):289-94
11489729
Clin Cancer Res. 2002 Apr;8(4):1168-71
11948129
J Cell Biol. 2005 Jul 18;170(2):191-200
16027218
Cancer Cell. 2003 May;3(5):471-82
12781365
Biochem Pharmacol. 2004 Sep 15;68(6):1199-208
15313417
Mol Cell Biol. 2001 Jan;21(1):39-50
11113179
J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):135-42
11384871
J Natl Cancer Inst. 2001 Nov 21;93(22):1687-97
11717329
J Urol. 2000 Dec;164(6):1992-5
11061898
Nat Med. 2004 Jan;10(1):33-9
14702632
Genes Dev. 2006 Jun 15;20(12):1569-74
16778075
Prostate. 2006 Jun 15;66(9):895-902
16496415
J Natl Cancer Inst. 2000 Dec 6;92(23):1918-25
11106683
Urol Clin North Am. 2006 May;33(2):201-10, vii
16631458
Mol Endocrinol. 1997 Apr;11(4):450-9
9092797
J Biol Chem. 2003 Dec 19;278(51):50902-7
14555644
Hum Mol Genet. 2001 Aug 15;10(17):1807-17
11532990
Cancer Cells. 1990 Nov;2(11):345-54
2282250
Cancer Res. 1998 Oct 15;58(20):4640-5
9788616
Am J Pathol. 2003 Jan;162(1):233-41
12507906
J Biol Chem. 2004 Feb 20;279(8):7119-30
14662770
Prostate. 2003 May 1;55(2):128-39
12661038
Cancer Res. 2003 Nov 15;63(22):7638-40
14633682
J Clin Invest. 2002 Aug;110(3):351-60
12163454
Cancer Res. 1994 Jun 1;54(11):2861-4
8187068
Exp Cell Res. 1999 Dec 15;253(2):349-56
10585257
Cancer Res. 1999 Jan 15;59(2):279-84
9927031
Exp Cell Res. 2006 Oct 1;312(16):3165-83
16860317
Cancer Res. 1999 Feb 15;59(4):803-6
10029066
Mol Cell Biol. 2002 Jun;22(11):3621-32
11997499
Cancer Metastasis Rev. 2001;20(3-4):207-23
12085963
Cancer Res. 1994 Oct 15;54(20):5474-8
7522959
Cancer Res. 2001 Jun 1;61(11):4315-9
11389051
Mol Endocrinol. 2006 May;20(5):1048-60
16373395
Mol Endocrinol. 1998 Aug;12(8):1172-83
9717843
J Pathol. 2000 Jul;191(3):239-44
10878544
Surg Oncol. 2005 Aug;14(2):91-104
15993579
Cancer Res. 1998 Dec 15;58(24):5718-24
9865729
Int J Cancer. 1991 May 10;48(2):189-93
1708363
Cancer Res. 1999 May 1;59(9):2203-9
10232609
Trends Mol Med. 2004 Apr;10(4):194-9
15059611
J Urol. 2003 Nov;170(5):1817-21
14532783
Hum Mutat. 1999;14(2):103-14
10425033
J Biol Chem. 2006 Sep 22;281(38):27882-93
16870607
Endocr Relat Cancer. 2004 Dec;11(4):709-24
15613447
Clin Cancer Res. 2003 Nov 1;9(14):5271-81
14614009
Nature. 1997 Sep 11;389(6647):194-8
9296499
FEBS Lett. 2002 Aug 28;526(1-3):142-6
12208521
Eur J Cancer. 2006 Jun;42(9):1213-8
16632344
Trends Endocrinol Metab. 2001 Jul;12(5):186-8
11592245
J Biol Chem. 2003 Feb 14;278(7):5052-61
12441355
Br J Cancer. 2001 Dec 14;85(12):1928-36
11747336
Cancer Res. 1999 Jun 1;59(11):2511-5
10363963
Clin Cancer Res. 2005 Jul 1;11(13):4653-7
16000557